- Home
- DCTH
DCTH
Delcath Systems Inc.
as 07-26-2024 4:00pm EST
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | QUEENSBURY |
| Market Cap: | 224.2M | IPO Year: | N/A |
| Target Price: | $19.83 | AVG Volume (30 days): | 214.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $9.18 | Next Earning Date: | 08-07-2024 |
| Revenue: | $4,607,000 | Revenue Growth: | 56.75% |
| Revenue Growth (this year): | 1280.77% | Revenue Growth (next year): | 153.69% |
Stock Insider Trading Activity of Delcath Systems Inc. (DCTH)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SALAMON STEVEN A J | DCTH | Director | Mar 19 '24 | Buy | $3.72 | 26,882 | $100,001.04 | 1,121,025 | SEC Form 4 |
| Aharon Gil | DCTH | Director | Mar 19 '24 | Buy | $3.72 | 26,882 | $100,001.04 | 1,069,710 | SEC Form 4 |
| Vukovic Vojo | DCTH | Chief Medical Officer | Dec 12 '23 | Buy | $3.00 | 40,000 | $120,000.00 | 100,000 | SEC Form 4 |
| MICHEL GERARD J | DCTH | Chief Executive Officer | Dec 8 '23 | Buy | $2.94 | 34,000 | $99,960.00 | 262,345 | SEC Form 4 |
| Rosalind Advisors, Inc. | DCTH | Director | Nov 17 '23 | Buy | $2.40 | 100,000 | $240,410.00 | 1,038,828 | SEC Form 4 |
| Vukovic Vojo | DCTH | Chief Medical Officer | Nov 16 '23 | Buy | $2.48 | 60,000 | $148,800.00 | 60,000 | SEC Form 4 |
Latest Delcath Systems Inc. News
DCTH Breaking Stock News: Dive into DCTH Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Delcath Systems to Host Second Quarter 2024 Earnings Call
Simply Wall St.
12 days ago
Breakeven On The Horizon For Delcath Systems, Inc. (NASDAQ:DCTH)
Simply Wall St.
a month ago
Investors in Delcath Systems (NASDAQ:DCTH) have unfortunately lost 90% over the last five years
Business Wire
2 months ago
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors
GuruFocus.com
2 months ago
Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
PR Newswire
2 months ago
Delcath Systems Reports First Quarter 2024 Results and Business Highlights
PR Newswire
3 months ago
Delcath Systems to Host First Quarter 2024 Earnings Call
PR Newswire
3 months ago
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
Compare DCTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DCTH Delcath Systems Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.